These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19123461)

  • 1. Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.
    Siragusa S; Passamonti F; Cervantes F; Tefferi A
    Am J Hematol; 2009 Mar; 84(3):140-3. PubMed ID: 19123461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
    Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
    Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second allogeneic stem cell transplantation in myeloid malignancies.
    Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
    Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
    de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and old treatment modalities in primary myelofibrosis.
    Cervantes F; Mesa R; Barosi G
    Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern management of myelofibrosis.
    Cervantes F
    Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
    Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
    Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation as treatment for myelofibrosis.
    Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
    Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for myelofibrosis.
    van Besien K; Deeg HJ
    Semin Oncol; 2005 Aug; 32(4):414-21. PubMed ID: 16202687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.
    Abelsson J; Merup M; Birgegård G; WeisBjerrum O; Brinch L; Brune M; Johansson P; Kauppila M; Lenhoff S; Liljeholm M; Malm C; Remes K; Vindelöv L; Andréasson B;
    Bone Marrow Transplant; 2012 Mar; 47(3):380-6. PubMed ID: 21552298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
    Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
    Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
    Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
    Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004.
    Bacher U; Klyuchnikov E; Zabelina T; Ottinger H; Beelen DW; Schrezenmeier H; Ehninger G; Müller C; Berger J; Suttorp M; Kolb HJ; Kröger N; Zander AR
    Ann Hematol; 2009 Dec; 88(12):1237-47. PubMed ID: 19319532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.